In this slide contains types of HPLC Columns, Plate theory and Van Deemter Equation.
Presented by : Malarvannan.M (Department of pharmaceutical analysis).
RIPER,anantpur.
The drug or drug combination may not be official in any pharmacopoeias.
A proper analytical procedure for the drug may not be available in the literature due to patent regulations.
Analytical methods may not be available for the drug in the form of a formulation due to the interference caused by the formulation excipients.
Analytical methods for the quantitation of the drug in biological fluids may not be available.
Analytical methods for a drug in combination with other drugs may not be available.
The existing analytical procedures may require expensive reagents and solvents. It may also involve cumbersome extraction and separation procedures and these may not be reliable.
In this slide contains types of HPLC Columns, Plate theory and Van Deemter Equation.
Presented by : Malarvannan.M (Department of pharmaceutical analysis).
RIPER,anantpur.
The drug or drug combination may not be official in any pharmacopoeias.
A proper analytical procedure for the drug may not be available in the literature due to patent regulations.
Analytical methods may not be available for the drug in the form of a formulation due to the interference caused by the formulation excipients.
Analytical methods for the quantitation of the drug in biological fluids may not be available.
Analytical methods for a drug in combination with other drugs may not be available.
The existing analytical procedures may require expensive reagents and solvents. It may also involve cumbersome extraction and separation procedures and these may not be reliable.
Ion pair chromatography for pharmacy studentsabhishek rai
Ion-PairChromatography
A GENERALISED OVERVIEW
Chromatography
HPLC
Reverse Phase Chromatography
Ion Pair Chromatography
Ion Pair Reagent
Mechanism of Ion Pair Chromatography
Ion Pair Wash Procedure
Particle Size Analysis by Laser Diffraction Method. AshviniTanpure
For Determination of Particle Size various method are used. here I mentioned the Laser Light scattering for determining the Particle Size. Mainly two type of laser scattering are used,
1. Static laser light scattering.
2. Dynamic laser light scattering.
detail about there principle we see in the slide .
.
.
.
If in any point you didn't understood ,you can contact with me.
hope it useful to you.
Thank You.
Analytical method development and validation for simultaneous estimationProfessor Beubenz
Brief about analytical method development and validation
Subscribe to the YouTube Channel #Professor_Beubenz
https://www.youtube.com/channel/UC84jGf2iRN5VjwnQqi6qmXg?view_as=subscriber
fluid chromatography (SFC) can be used on an analytical
scale.
It is a combination of High performance liquid chromatography (HPLC)
and Gas chromatography (GC).
It can be used with non-volatile and thermally labile analytes.
It can be used with the universal flame ionization detector.
It is important to producing narrower peaks due to rapid diffusion.
It is important for the chiral separations and analysis of high-molecularweight
hydrocarbons.
Supercritical fluids are suitable as a substitute for organic solvents in a
range of industrial and laboratory processes.
Method Validation - Limit of Detection, Quantitation limits and Robustnesslabgo
Prepared By: Shruti Vij (Senior Analyst) , Geeta Mathur(Senior Scientist) ,Khushbu ( Analyst)
This slide show contains detailed explanation of three characteristics of method validation- Limit of detection, Quantitation limits and Robustness. Limit of detection is the minimum amount of substance that can be detected but not measured, quantitation limit is the minimum amount of substance which can be detected and measured. Common approach to these procedures- signal to noise ratio has also been covered. Robustness is a characteristic which determines a method’s reliability when deliberate variations are induced in parameters.
Stability indicating analytical method development and validation for estimat...SriramNagarajan18
Stability indicating analytical method development and validation for estimation of Sacubitril and Valsartan in bulk and pharmaceutical dosage form using RP-HPLC
Ion pair chromatography for pharmacy studentsabhishek rai
Ion-PairChromatography
A GENERALISED OVERVIEW
Chromatography
HPLC
Reverse Phase Chromatography
Ion Pair Chromatography
Ion Pair Reagent
Mechanism of Ion Pair Chromatography
Ion Pair Wash Procedure
Particle Size Analysis by Laser Diffraction Method. AshviniTanpure
For Determination of Particle Size various method are used. here I mentioned the Laser Light scattering for determining the Particle Size. Mainly two type of laser scattering are used,
1. Static laser light scattering.
2. Dynamic laser light scattering.
detail about there principle we see in the slide .
.
.
.
If in any point you didn't understood ,you can contact with me.
hope it useful to you.
Thank You.
Analytical method development and validation for simultaneous estimationProfessor Beubenz
Brief about analytical method development and validation
Subscribe to the YouTube Channel #Professor_Beubenz
https://www.youtube.com/channel/UC84jGf2iRN5VjwnQqi6qmXg?view_as=subscriber
fluid chromatography (SFC) can be used on an analytical
scale.
It is a combination of High performance liquid chromatography (HPLC)
and Gas chromatography (GC).
It can be used with non-volatile and thermally labile analytes.
It can be used with the universal flame ionization detector.
It is important to producing narrower peaks due to rapid diffusion.
It is important for the chiral separations and analysis of high-molecularweight
hydrocarbons.
Supercritical fluids are suitable as a substitute for organic solvents in a
range of industrial and laboratory processes.
Method Validation - Limit of Detection, Quantitation limits and Robustnesslabgo
Prepared By: Shruti Vij (Senior Analyst) , Geeta Mathur(Senior Scientist) ,Khushbu ( Analyst)
This slide show contains detailed explanation of three characteristics of method validation- Limit of detection, Quantitation limits and Robustness. Limit of detection is the minimum amount of substance that can be detected but not measured, quantitation limit is the minimum amount of substance which can be detected and measured. Common approach to these procedures- signal to noise ratio has also been covered. Robustness is a characteristic which determines a method’s reliability when deliberate variations are induced in parameters.
Stability indicating analytical method development and validation for estimat...SriramNagarajan18
Stability indicating analytical method development and validation for estimation of Sacubitril and Valsartan in bulk and pharmaceutical dosage form using RP-HPLC
Assignment 01: Discuss the different ways of particle diameter expression. Also to calculate the equation of particle number for 1 gram of powder sample. A little assignmen on the topic based on micromeritics.
Powder Technology
Particle analysis in pharmaceuticals
Determination of particle size and surface area
Large scale equipment for powders
Types of powders
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
2. FDA guidance: when should particle size be
measured?
International Conference on Harmonization;
Guidance on Q6A Specifications:
Test Procedures and Acceptance Criteria for New Drug
Substances and New Drug Products: Chemical Substances*
3.3.1 New Drug Substances
(b) Particle size: For some new drug substances intended for use in solid
or suspension drug products, particle size can have a significant effect on
dissolution rates, bioavailability, and/or stability. In such instances, testing
for particle size distribution should be carried out using an appropriate
procedure, and acceptance criteria should be provided.
Decision Tree #3 provides additional guidance on when particle size
testing should be considered.
4. Method Development
Goal: Reproducible method that tracks product
performance
Choose measurement approach (dry vs. wet)
Lock down RI
Vary measurement settings that can influence result
Dry: measurement duration, concentration, air pressure
Wet: sampler selection, dispersion, duration,
concentration, energy (mixing + ultrasound)
Test method (reproducibility)
Meet ISO, USP or internal guidelines
Check COV at d10, d50, d90
5. Goals
Reproducible method that tracks product
performance
Use structured approach for any decision/choice that
may influence result
Have data to support selections made
Document process so others (in future) understand
the decisions
6. Method development: available guidance
for laser diffraction measurements
ISO13320-1: Section 6.4
Dv50 - 5 different readings: COV < 3%
Dv10 and Dv90: COV < 5%
“Below 10μm, these maximum values should be doubled.”
USP <429>
Provides reproducibility ranges
Dv50 or any central value: <10%
Dv10, Dv90 or any non-central value: <15%
“Below 10μm, these maximum values should be doubled.”
EP 2.9.31 provides similar advice to USP<429>
9. Technique: Grab Sampling
PLACE SPATULA INTO POWDER
EXTRACT SMALL AMOUNT FOR ANALYSIS
ACCEPTABLE FOR NARROW DISTRIBUTIONS
SEGREGATE LARGE AND SMALL WHEN POLYDISPERSE
LARGE PARTICLES PERCOLATE UPWARD
SMALL PARTICLES GRAVITATE DOWNWARD
EASY METHOD
MOST USED METHOD
10. Grab Sampling from Bottle
When a powder is stored in a container,
it can be mixed by rolling and tumbling
the container. The container should not
be more than half to two-thirds full. It is
important to perform this action before
“grabbing” a sample with a spatula.
Then pull sample with a spatula…..
17. Choosing the Solvent (Dispersent)
When powders are dispersed in liquid the
solvent must meet the following criteria:
Negligible reactivity with powder
Does not swell or shrink particles
Have refractive index (RI) different than the sample
Be free from bubbles & particles
Have suitable viscosity to enable recirculation
Be compatible with materials in the analyzer
20. How to check for wetting
If the particles float on top and do not penetrate the water surface,
they are not wetted. This is usually a bad sign.
If the particles break through surface and sink, they are a) wetted or
b) so big that gravity is more important than surface tension. If it is
case you are in luck!
26. Refractive Index
Refractive Index is defined by two components – REAL and
IMAGINARY
RI = n + ik
Where:
n = the real component, which is the ratio of the velocity of
light in a vacuum to the velocity of light in the material =
c/vp
c = speed of light in vacuum
Vp = speed of light in particle (liquid, air)
k = the extinction coefficient of the material
i = √ - 1
27. Determine RI
Real component via literature or web search, Becke
line, etc.
Measure sample, vary imaginary component to see
if/how results change
Recalculate using different imaginary components,
choose
value that minimizes R parameter error calculation
28. RI: Imaginary Component
For transparent particles use 0 for the
imaginary component
For slightly opaque materials use 0.01
or 0.1
For opaque materials use 1.0 or higher
Values can exceed 1.0 (see below*)
32. Detection limit and Range
Assessment of the detection limit of the laser
diffraction technique is not required as part of
method validation.
The range of the instrument should ideally
cover the size range of the sample. For
modern laser diffraction instrumentation with
size ranges between 20nm and 2000μm this
normally presents no problem for most
pharmaceutical samples.
33. Specificity
Specificity, in terms of whether or not the technique
is appropriate to the material under analysis, should
be addressed as part of method development and
does not have to be revisited for method validation.
Laser diffraction provides a good method for
assessing small changes in the size distribution in this
regard. However, it is difficult to differentiate
between the different components within
pharmaceutical dosage forms using the technique.
35. Measurement Duration
The purpose of this exercise is to determine a suitable
measurement duration, which will then be used for the
repeatability, reproducibility and intermediate precision
exercises.
A cycle of ten measurements should be performed for durations
of 2, 5, 7, 10 and 15 seconds.
For particles with a median size (D(v,0.5)) of >10 micron the
Relative Standard Deviation (RSD) should be <3%
For particles with a median size <10 micron the RSD must be
<6%. This reflects the Fact that smaller particles are more
difficult to disperse.
37. Repeatability /
Sample Measurement Stability
In order to determine whether samples are stable over the
period of analysis and not subject to agglomeration, de-
agglomeration or dissolution, it is necessary to monitor the
particle size distribution at known time points.
Measurements could be taken after 1, 3, 5, 7 and 10 minutes.
At least five repeat measurements should be obtained at each
time point.
For material that has a D(v,0.5) greater than 10 microns an
acceptable time point is defined when the following conditions
are met: D(v,0.5) RSD <3%, D(v,0.1) and D(v,0.9) RSD <5%.
For material that has a D(v,0.5) less than 10 microns an
acceptable time point is defined when the following conditions
are met: D(v,0.5) RSD <6%, D(v,0.1) and D(v,0.9) RSD <10%
(ISO13320).
39. Air Pressure (Dry measurement) /
Ultrasound (wet measurement)
A suitable pressure is one at which dispersion of the particles is
achieved but milling of the particles is not occurring.
Often both dispersion and milling occur simultaneously (which
leads to a broadening of the distribution)
By measuring the same amount of sample (ideally sampled to
single shot size by a spinning riffler) at different pressures, the
pressure at which maximum dispersion is achieved without
milling can be ascertained.
The use of ultrasound in wet measurements is very similar. ISO
13320 recommends that ultrasound can be used to assist
dispersion. Too much ultrasound can fracture friable
pharmaceutical particles, although this is extremely unusual.
Ideally measurements should be taken before, during and after
ultrasound to examine what effect sonication has on the
robustness of the measurement.
41. Pump and Stir Rates
The pump and stir speeds used during
a measurement should be examined as
part of method development. The
chosen conditions should be capable of
suspending all the material without
causing air entrainment (a particular
problem if surfactants are being used).
42. Pump and Stir Rates
Effect of varying the stirrer rate on the result obtained for a typical lactose.
43. Linearity / Obscuration
It is suggested
that
obscurations of
5, 10, 15,
20 and 25% are
investigated in
the same way
that the
measurement
duration test
was
performed, with
the acceptable
RSDs being
similarly
specified.
48. Method Development: Dry
First get sampling right & determine RI
Measure at 3 different pressures (low, medium, high)
Determine optimum pressure based on good
dispersion while not breaking particles
Can also compare dry vs. wet measurements
Adjust other settings to optimize sample concentration &
duration
Ideally measure all of powder placed into the sampler
Segregation can occur on vibrating tray
Constant mass flow rate important for stable concentration
during measurement
Once settings chosen, test reproducibility
49. FDA Recommendations
The FDA’s guidance regarding the validation of
particle size analysis methods states that the
validation concepts associated with other analytical
methodologies, such as HPLC, do not transfer to
techniques such as laser diffraction. Instead, analysts
are only required to assess the intermediate precision
and robustness in order to show that the selected
method provides a reproducible method of controlling
product quality
50. Conclusions
Must have representative sample
Powders: select air pressure
Suspensions: wet, disperse
Check accuracy w/microscope
Investigate system settings:
Concentration, agitation, ultrasound
Design for maximum precision
Follow guidelines in standards
51. “Quality cannot be tested into
products; i.e., quality should be
built in by design”- ICH
THANK YOU FOR YOUR
ATTENTION!